Valuation: Orexo AB

Market Cap 546M 57.21M 49.56M 46.44M 42.36M 79.63M 5.46B 80.85M 213M 2.73B 215M 210M 9.11B P/E 2026 *
-1.49x
P/E 2027 * -2.15x
Enterprise Value 441M 46.21M 40.03M 37.51M 34.21M 64.32M 4.41B 65.31M 172M 2.21B 173M 170M 7.36B EV / Sales 2026 *
23.2x
EV / Sales 2027 * 14.7x
Free-Float
70.1%
Yield 2026 *
-
Yield 2027 * -
1 day+7.71%
1 week+8.91%
Current month+6.39%
1 month-32.59%
3 months-15.73%
6 months-43.94%
Current year-48.04%
1 week 14.22
Extreme 14.22
16.12
1 month 13.7
Extreme 13.7
24.6
Current year 13.7
Extreme 13.7
36
1 year 13.7
Extreme 13.7
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 2013-02-04
Director of Finance/CFO 59 2022-08-31
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 64 2001-12-31
Director/Board Member 70 2019-04-10
Director/Board Member 62 2022-03-31
Date Insider Type Main position Quantity % Market Cap.
9/4/25 Buy

Chief Executive Officer

6 0.0000%
9/4/25 Free

Chief Executive Officer

1,393 0.0040%
9/3/25 Free 149 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+7.71%+8.91%-19.79%-14.54% 53.3M
+1.92%+3.58%+65.53%+23.72% 322B
0.00%-3.45%+26.07%-14.27% 70.24B
-0.81%+21.77%+58.95%+132.66% 11.65B
-0.75%+2.35%-2.20%-3.65% 8.42B
-2.54%+7.56%-10.73%-6.86% 5.02B
-2.92%+10.65%-25.14%+15.26% 4.52B
-0.76%+13.44%+2.89%+48.08% 4.25B
+2.11%+2.05%+16.08%+50.11% 2.72B
-2.00%-0.14%-1.79%-1.14% 2.28B
Average +0.20%+5.67%+10.99%+22.94% 43.09B
Weighted average by Cap. +1.33%+3.04%+54.46%+19.76%

Financials

2026 *2027 *
Net sales 19M 1.99M 1.72M 1.62M 1.47M 2.77M 190M 2.81M 7.43M 95.04M 7.47M 7.31M 317M 27.5M 2.88M 2.5M 2.34M 2.13M 4.01M 275M 4.07M 10.75M 138M 10.81M 10.58M 459M
Net income -375M -39.28M -34.03M -31.88M -29.08M -54.67M -3.75B -55.51M -147M -1.88B -147M -144M -6.25B -270M -28.33M -24.55M -23M -20.98M -39.44M -2.7B -40.04M -106M -1.35B -106M -104M -4.51B
Net Debt -105M -11M -9.53M -8.93M -8.14M -15.31M -1.05B -15.54M -41.04M -525M -41.29M -40.39M -1.75B -143M -14.98M -12.98M -12.16M -11.09M -20.85M -1.43B -21.17M -55.9M -715M -56.23M -55.01M -2.39B
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Date Price Change Volume
26-08-12 SEK 15.64 +7.71% 63,436
26-08-11 SEK 14.52 -2.55% 22,844
26-08-10 SEK 14.90 +1.50% 8,267
26-08-07 SEK 14.68 +2.37% 24,885
26-08-06 SEK 14.34 -0.14% 43,533
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise